title: Anti-thrombotic effect of chronic oral treatment with Orbignya phalerata Mart.
abstract: Babassu is the popular name of Orbignya phalerata Mart. (Arecaceae). The mesocarp flour obtained from their fruits has been used in Brazil as medicine in the treatment of pains, constipation, obesity, leukemia, rheumatism, ulcerations, tumors, inflammations and venous diseases. The effect of the chronic oral treatment with aqueous extract of babassu mesocarp (500mg/kgday) on the number of platelets, the prothrombin time (PT), the activated partial thromboplastin time (aPTT), the nitric oxide (NO) production and the carrageenin-induced thrombosis was evaluated, using C57Bl/6 mice. The chronic oral treatment with babassu mesocarp induced an anti-thrombotic effect. There was a 88.9% reduction in the necrosis of the tail. This effect seems to be related to an increase in the ability of the macrophage to produce NO and to a slow coagulation process associated to an increase of 12.0 and 13.9% in PT and aPTT, respectively. However, the anti-thrombotic effect seems to be not related to alterations in the number of platelets. It is possible to conclude that the oral treatment with babassu mesocarp has a significant anti-thrombotic effect, which could justify the popular use of babassu mesocarp in the treatment of venous diseases. Meanwhile, this study suggests a potential use of babassu mesocarp as a prophylactic agent to avoid thrombosis events.
authors.affiliation: Laboratório de Imunofisiologia, Centro de Ciências Biológicas e da Saúde, Universidade Federal do Maranhão, Av dos Portugueses, s/n, Campus do Bacanga, São Luís, MA, Brazil.
authors.forename: Ana Paula S
authors.initials: AP
authors.lastname: Azevedo
authors.forename: Jardel C
authors.initials: JC
authors.lastname: Farias
authors.forename: Graciomar C
authors.initials: GC
authors.lastname: Costa
authors.forename: Susanne C P
authors.initials: SC
authors.lastname: Ferreira
authors.forename: Walmir C
authors.initials: WC
authors.lastname: Aragão-Filho
authors.forename: Paulo R A
authors.initials: PR
authors.lastname: Sousa
authors.forename: Mayara T
authors.initials: MT
authors.lastname: Pinheiro
authors.forename: Márcia C G
authors.initials: MC
authors.lastname: Maciel
authors.forename: Lucilene A
authors.initials: LA
authors.lastname: Silva
authors.forename: Adelson S
authors.initials: AS
authors.lastname: Lopes
authors.forename: Elizabeth S B
authors.initials: ES
authors.lastname: Barroqueiro
authors.forename: Marilene O R
authors.initials: MO
authors.lastname: Borges
authors.forename: Rosane N M
authors.initials: RN
authors.lastname: Guerra
authors.forename: Flávia R F
authors.initials: FR
authors.lastname: Nascimento
mesh_terms: D000284:Administration, Oral; D000818:Animals; D028023:Arecaceae; D001777:Blood Coagulation / Q000187:drug effects*; D001792:Blood Platelets / Q000187:drug effects*; D001938:Brazil; D002351:Carrageenan; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D005638:Fruit; D017737:Macrophages, Peritoneal / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D009336:Necrosis; D009569:Nitric Oxide / Q000378:metabolism; D010314:Partial Thromboplastin Time; D010936:Plant Extracts / Q000494:pharmacology; D010976:Platelet Count; D011517:Prothrombin Time; D013623:Tail / Q000473:pathology; D013927:Thrombosis / Q000097:blood / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors
chemical_list: D005343:Fibrinolytic Agents; D010936:Plant Extracts; D009569:Nitric Oxide; D002351:Carrageenan